The abstract is read at the publisher; the summary is JClub's.
Teclistamab treatment in 10 severe, treatment-refractory systemic sclerosis patients is linked to near-complete elimination of bone marrow and skin B-cells and plasma cells, with a median 70.6% antitopoisomerase antibody titre reduction.
- Why it matters: Severe systemic sclerosis has limited options, and the field lacks clear evidence that BCMA-directed T-cell engagement can rapidly reshape immune activity and improve clinical and serologic measures.
- What they did: Off-label teclistamab was given to severe, refractory SSc patients, with blood and tissue assessed by immunohistochemistry and flow cytometry and serum antibodies measured by ELISA; efficacy used revised ACR-CRISS responses.
- The result: After a median 3.75 months follow-up, 71% and 43% achieved revised ACR-CRISS 25 and 50 responses, respectively, alongside week-12 interstitial lung disease improvement (median FVC +7%) and skin score reduction (median modified Rodnan −35.9%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.